Response
- PMID: 24493529
- PMCID: PMC3921095
- DOI: 10.1378/chest.13-2519
Response
Comment on
-
WHO's in second?: A practical review of World Health Organization group 2 pulmonary hypertension.Chest. 2013 Aug;144(2):638-650. doi: 10.1378/chest.12-2114. Chest. 2013. PMID: 23918108 Free PMC article. Review.
-
Pulmonary hypertension drugs were never properly tested in heart failure.Chest. 2014 Feb;145(2):420. doi: 10.1378/chest.13-2121. Chest. 2014. PMID: 24493528 No abstract available.
References
-
- Califf RM, Adams KF, McKenna WJ, et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST). Am Heart J. 1997;134(1):44-54 - PubMed
-
- Bonderman D, Ghio S, Felix SB, et al. ; Left Ventricular Systolic Dysfunction Associated With Pulmonary Hypertension Riociguat Trial (LEPHT) Study Group Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study. Circulation. 2013;128(5):502-511 - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
